8-KEarnings & ResultsExhibits & Filings

BeOne Medicines Ltd. 8-K Report, Financial Results (Apr 14, 2026)

Filed April 14, 2026For Securities:ONCBEIGF

Summary

BeOne Medicines Ltd. (ONC) has filed its 2025 Annual Report with the Shanghai Stock Exchange's STAR Market, adhering to PRC accounting standards. This report, presented in Chinese, includes financial information for the year ended December 31, 2025, prepared in accordance with China Accounting Standards for Business Enterprises (CAS) and other PRC GAAP. Importantly, for U.S. investors, the Company has furnished supplementary financial information as an exhibit to this 8-K filing. This exhibit provides key metrics such as gross profit margin, R&D expenses broken down by product and project, and production/sales/inventory data for 2025, all prepared under U.S. GAAP. It also details the material differences between PRC GAAP and U.S. GAAP. This filing serves as a crucial update for investors, bridging the information gap between the primary Chinese filing and U.S. reporting requirements. Investors should pay close attention to Exhibit 99.1, which offers a U.S. GAAP perspective on the company's financial performance and operational metrics. The availability of this U.S. GAAP reconciled data is vital for a comprehensive understanding of BeOne Medicines' financial health and operational status for the 2025 fiscal year.

Key Highlights

  • 1BeOne Medicines Ltd. filed its 2025 Annual Report with the Shanghai Stock Exchange STAR Market on April 14, 2026.
  • 2The primary annual report is prepared in accordance with PRC GAAP and is available in Chinese.
  • 3An exhibit (99.1) to the 8-K filing provides U.S. GAAP financial information for 2025.
  • 4Exhibit 99.1 includes gross profit margin, R&D expenses by product/project, and production/sales/inventory data under U.S. GAAP.
  • 5The filing also details material differences between PRC GAAP and U.S. GAAP.
  • 6The furnished information in this 8-K is intended for U.S. investors to facilitate a U.S. GAAP understanding of the company's performance.

Frequently Asked Questions

The complete 2025 Annual Report, prepared in accordance with PRC GAAP, is available in Chinese on the Shanghai Stock Exchange website at www.sse.com.cn. Please note this filing is not part of the SEC filing and is not incorporated by reference.

Exhibit 99.1 is crucial for U.S. investors as it provides key financial and operational data for the year ended December 31, 2025, prepared under U.S. GAAP. It also outlines the differences between PRC GAAP and U.S. GAAP, allowing for a more direct comparison and understanding of the company's performance from a U.S. accounting perspective.

This 8-K filing, specifically Exhibit 99.1, includes specific financial metrics and operational data prepared under U.S. GAAP, such as gross profit margin, R&D expenses, and inventory data. It also highlights material differences between PRC GAAP and U.S. GAAP. However, it may not contain the full suite of U.S. GAAP financial statements, which are primarily presented in the Chinese annual report under PRC GAAP.

The information in Item 2.02 and Exhibit 99.1 of this Current Report on Form 8-K is furnished, not filed. This means it is not subject to the liabilities of Section 18 of the Exchange Act, nor is it automatically incorporated by reference into other SEC filings unless specifically referenced.